---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-062903"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2023-11-13T23:59:59+00:00"
generated_at: "2026-06-08T05:21:32.502345+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology Q3 net loss $51.0M; positive Phase 2 gastric cancer data; CEO change

## Summary
- Q3 2023 GAAP net loss $51.0M ($1.24/diluted share) vs $35.3M ($0.87) in Q3 2022.
- Cash, equivalents and investments $196.4M; runway into early 2026 including recent $63.2M offering proceeds.
- Interim Phase 2 ASPEN-06: confirmed ORR 52% for evorpacept combo arm vs 22% for control in HER2+ gastric/GEJ cancer.
- Leadership realignment: Jason Lettmann appointed CEO, Jaume Pons becomes President and CSO.
- Closed public offering of common stock and pre-funded warrants in Oct 2023 for gross proceeds ~$63.2M.

## SEC filing metadata
- accession: 0000950170-23-062903
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2023-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017023062903/0000950170-23-062903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017023062903/alxo-20231113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-062903
- JSON: https://secwatch.observer/filing/0000950170-23-062903.json
- Plain text: https://secwatch.observer/filing/0000950170-23-062903.txt

## Key facts
- Earnings Releases
  ALX ONCOLOGY HOLDINGS INC reported financial results for the third quarter ended September 30, 2023.
  - Period: the third quarter ended September 30, 2023
  - Result: reported results
  source text: On November 13, 2023, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the third quarter ended September 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017023062903/0000950170-23-062903-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.